- Home
- GRFS
GRFS
Grifols S.A.
as 03-28-2025 4:00pm EST
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
| Founded: | 1940 | Country: | Spain |
| Employees: | N/A | City: | N/A |
| Market Cap: | 5.1B | IPO Year: | 2006 |
| Target Price: | N/A | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.24 | EPS Growth: | 283.33 |
| 52 Week Low/High: | $5.79 - $9.96 | Next Earning Date: | 01-01-0001 |
| Revenue: | $7,467,006,939 | Revenue Growth: | 9.41% |
| Revenue Growth (this year): | 8.45% | Revenue Growth (next year): | 7.08% |
Latest Grifols S.A. News
GRFS Breaking Stock News: Dive into GRFS Ticker-Specific Updates for Smart Investing
Simply Wall St.
19 days ago
High Growth Tech Stocks in Europe for March 2025
MT Newswires
a month ago
Grifols Aims to Double Revenue Over Next Decade
Insider Monkey
a month ago
Is Grifols, S.A. (GRFS) the Best Low Price Pharma Stock to Invest In Right Now?
GuruFocus.com
a month ago
Grifols SA (GIFLF) (Q4 2024) Earnings Call Highlights: Record Revenues and Strategic ...
MT Newswires
a month ago
Grifols to Appoint Anne-Catherine Berner as Chair
Simply Wall St.
2 months ago
Exploring High Growth Tech Stocks In February 2025
Bloomberg
2 months ago
Gotham, Grifols Eye Two Separate Regulator Reports Ahead of Legal Standoff
MT Newswires
2 months ago
Grifols Gets $21 Million Grant to Identify Early Parkinson's Disease Biomarkers
Compare GRFS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GRFS Grifols S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.